Pharmacological Targeting of DHHC9-STRN4 Palmitoylation: A Novel Strategy to Inhibit YAP-Driven Cancer Metastasis

Study Background and Research Question

Protein S-palmitoylation, the reversible attachment of palmitate to cysteine residues, is a critical post-translational modification (PTM) influencing protein localization, stability, and function. Among the enzymes mediating this process, the DHHC family of palmitoyl transferases has emerged as a key regulator of oncogenic signaling pathways. Although some DHHC enzymes are linked to tumorigenesis, the cancer-specific roles and substrates of individual members remain poorly characterized. The recent study by Yang Tian and colleagues (Journal of Cellular and Molecular Medicine, 2025) addresses a central question: How does DHHC9-mediated palmitoylation affect cancer metastasis, and can pharmacological inhibition of this pathway offer a viable therapeutic approach?

Key Innovation from the Reference Study

The study provides the first comprehensive evidence that DHHC9 is a crucial driver of adenocarcinoma metastasis via palmitoylation of STRN4, a core component of the STRIPAK complex. Notably, the authors demonstrate that DHHC9-catalyzed palmitoylation of STRN4 at cysteine 701 modulates the Hippo-YAP signaling axis, a pathway well-known for its role in cell migration and tumor progression. This mechanistic insight not only clarifies the functional relevance of DHHC9 in cancer but also identifies STRN4 palmitoylation as a tractable target for anti-metastatic therapy. Importantly, two small molecules—Treprostinil and 10-HCPT—are identified as effective DHHC9 inhibitors that suppress cancer cell migration, establishing a new pharmacological entry point for therapeutic intervention.

Methods and Experimental Design Insights

The research adopts a multi-layered experimental strategy, combining genetic, proteomic, and pharmacological approaches to dissect the functional role of DHHC9 in cancer metastasis:

• Genetic Manipulation: RNA interference (siRNA/shRNA) was used to knock down DHHC9 expression in colorectal and lung adenocarcinoma cell lines. The impact on cell migration was assessed using transwell and wound healing assays.
• In Vivo Models: Mouse xenograft models were employed to evaluate the effect of DHHC9 knockdown on tumor metastasis.
• Proteomics and Palmitoylation Mapping: Mass spectrometry-based proteomic analyses identified STRN4 as a direct substrate of DHHC9. Site-directed mutagenesis confirmed cysteine 701 as the palmitoylation site.
• Functional Pathway Analysis: The study assessed downstream effects on the Hippo-YAP pathway, including YAP phosphorylation, nuclear localization, and target gene activation (CCN1, CCN2, ANKRD1).
• Pharmacological Screening: Candidate small molecule inhibitors were screened for their ability to block DHHC9-mediated STRN4 palmitoylation and inhibit cancer cell migration.

Protocol Parameters

• DHHC9 knockdown: Lentiviral shRNA transduction; verify knockdown efficiency by qRT-PCR and immunoblotting before functional assays.
• Cell migration assays: Transwell migration for 24–48 hours post-treatment; wound healing monitored every 12 hours to quantify closure rates.
• In vivo metastasis models: Tail vein injection of engineered cancer cells into immunodeficient mice; monitor metastatic foci by bioluminescence or histology over 4–6 weeks.
• Palmitoylation detection: Acyl-biotin exchange chemistry followed by immunoprecipitation and mass spectrometry.
• Small molecule inhibitor treatment: Pre-treat cells with candidate inhibitors (e.g., Treprostinil, 10-HCPT) at 1–10 μM for 2–24 hours prior to functional assays.

Core Findings and Why They Matter

The reference study (Tian et al., 2025) reveals several pivotal insights:

• DHHC9 as a Metastatic Driver: Genetic silencing of DHHC9 significantly inhibits migration of adenocarcinoma cells in vitro and reduces metastatic colonization in vivo, highlighting its essential role in the metastatic cascade.
• STRN4 Palmitoylation: DHHC9 specifically palmitoylates STRN4 at cysteine 701. Loss of this modification impairs STRIPAK complex function and downstream signaling.
• YAP Activation and Hippo Pathway Dysregulation: Palmitoylated STRN4 promotes YAP nuclear translocation and activation of pro-migratory gene targets, linking DHHC9 activity to Hippo pathway output.
• Pharmacological Inhibition: Small molecules Treprostinil and 10-HCPT hinder STRN4 palmitoylation and YAP-mediated transcription, effectively suppressing cancer cell migration without overt cytotoxicity.

Collectively, these findings define the DHHC9-STRN4-YAP axis as a novel mechanism of cancer metastasis and establish DHHC9 as a druggable target for anti-metastatic intervention. The study also expands the landscape of actionable oncogenic pathways beyond classic kinase targets, suggesting new directions for targeted therapy development.

Comparison with Existing Internal Articles

Several internal analyses on the L1023 Anti-Cancer Compound Library highlight the value of curated, cell-permeable compound collections for high-throughput screening of anti-cancer agents and pathway interrogation. For example, internal workflows describe targeting challenging oncogenic drivers such as PLAC1 and leveraging pathway-focused libraries for biomarker-driven discovery (see here). The DHHC9-STRN4-YAP axis, as elucidated in the reference study, broadens the panel of potential metastatic targets accessible via such compound libraries. Moreover, the pharmacological screening approach used to identify DHHC9 inhibitors mirrors the high-content screening strategies supported by products like L1023, which encompasses agents against kinases, the mTOR signaling pathway, and other regulatory nodes relevant to Hippo/YAP signaling.

Limitations and Transferability

Despite its innovative findings, the study has certain limitations. The in vivo models are based on xenografts in immunocompromised mice, which may not fully capture the complexity of human tumor microenvironments. While STRN4 palmitoylation was mapped in colorectal and lung adenocarcinoma cells, the generalizability to other cancer types remains to be determined. Furthermore, the identified small molecule inhibitors, Treprostinil and 10-HCPT, require further optimization and validation in preclinical models to assess specificity, pharmacokinetics, and potential off-target effects. Translating these findings into clinical applications will require additional mechanistic studies and robust biomarker development to select responsive patient populations.

Research Support Resources

For researchers aiming to dissect palmitoylation-dependent oncogenic pathways or conduct high-throughput screening of anti-cancer agents—especially those targeting kinase signaling, the mTOR pathway, or novel regulatory mechanisms like DHHC9-STRN4-YAP—comprehensive compound resources are essential. The DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) offers a diverse, validated collection of 1,164 bioactive molecules, including BRAF kinase inhibitors and modulators of key cancer pathways, in a format suitable for reproducible screening and pathway analysis. Incorporating such a resource can facilitate the identification of novel modulators of palmitoylation or Hippo pathway activity in translational cancer research workflows. This aligns with the workflow-driven guidance described in internal resources, supporting advanced discovery efforts in metastasis and targeted therapy development.